FIELD: pharmaceutics.
SUBSTANCE: invention relates to novel conjugates of glucagon superfamily peptides, which are conjugated with the ligand that is capable of acting at a nuclear hormone receptor of type I.
EFFECT: present invention also refers to pharmaceutical compositions containing said conjugates, and methods of treating a disease, for example, a metabolic disorder, diabetes or obesity.
15 cl, 19 dwg, 15 tbl, 31 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| OXYINTOMODULINE | 2009 |
|
RU2542362C2 |
| GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
